Pre-treatment levels of sPD-L1 in NSCLC patients have been assessed by multiple investigators as a predictive biomarker for ICI therapy, with elevated levels reported in five studies representing 668 patients demonstrating a negative association with PFS and OS [32–36] (Table 2). Here, SPDL1 is linked to non-small cell lung carcinoma.